VWA
SIOX

V Wealth Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

V Wealth Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13
Closed -$2K – 747
2017
Q2 		$2K Buy
+13
New +$2.28K ﹤0.01% 766

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

V Wealth Advisors's SIOX Position: Q3 2017 in Review

V Wealth Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 13 shares — an estimated $2K sold.

V Wealth Advisors first reported a position in SIOX in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • V Wealth Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • V Wealth Advisors sold 13 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $2K.
  • V Wealth Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • V Wealth Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $2K in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.